RHAPSIDO is NOW APPROVED for symptomatic dermographism (SD) when antihistamines aren't enough1 | View the Data |
CSU patient portrayal.
The only oral targeted therapy with indications in both of the two most common types of chronic hives—chronic spontaneous urticaria (CSU) or symptomatic dermographism (SD)1-3,*
When antihistamines aren't enough for CSU or SD, cut to RHAPSIDO.1
Fast relief from hives and itch at week 12 in CSU1
In REMIX-2, RHAPSIDO (n=297) significantly reduced HSS7 and ISS7 vs placebo (n=153) at week 12 (LS mean CFB in HSS7: -10.47 vs -6.00; P<.001; LS mean CFB in ISS7: -8.95 vs -5.72; P<.001).1,4,†
Well-controlled CSU (UAS7 ≤6) results were seen as early as week 2 (30% [n=89] vs 6% [n=9]; P<.001).1,4,†
Fast, complete resolution of hives at week 12 in SD1
In RemIND, 29.3% of patients on RHAPSIDO (n=17/58) achieved complete response of hives based on TFS (TFS=0)‡ vs 14.0% of patients on placebo (n=8/57) at week 12 (one-sided P value=.0229)1,5,†
Demonstrated safety profile
RHAPSIDO has a robust safety evaluation and the safety profile in the RemIND trial for up to 24 weeks was consistent with the safety profile in the REMIX trials for up to 24 weeks.1
Cut to RHAPSIDO
†Multiple imputation techniques were implemented for missing data.1
‡A Fric test uses a 4-prong diagnostic tool that applies standardized, reproducible pressure to the skin, which induces hives among patients with SD. TFS refers to the number of prongs on the tool that induced hives when applied to the skin.1,6
§Limitations apply. Subject to annual co-pay benefit limit. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at rhapsido.com for details.